1. Clinical & Scientific Overview
Tranexamic Acid (Antifibrinolytic Haemorrhage Control) (TIP-MED-000245, Reference Code [12.13]) is classified under
Obstetric, Gynaecological & Antifibrinolytic Medicines (Ch 12) as a Antifibrinolytic Synthetic Lysine Analogue (Plasminogen Activation Inhibitor).
Within the Indian regulatory and compendial framework, it is governed under Schedule H Prescription Drug (To be sold by retail on the prescription of a Registered Medical Practitioner only — Drugs Rules 1945).
Representative Indian Market Examples (Edition 2.7 Ch 12 [12.13], p. 161): Trapic, Pause, Texakind, Trenaxa — Strengths & Dosage Forms: Tablet: 250 mg, 500 mg, 650 mg SR; Injection: 500 mg/5 mL (100 mg/mL ampoule).
Tablet: 250 mg, 500 mg, 650 mg SR; Injection: 500 mg/5 mL (100 mg/mL ampoule).
3. Mechanism of Action & Pharmacodynamics
Reversibly binds lysine-binding sites on plasminogen and plasmin -> blocks plasmin from binding to fibrin -> stabilises preformed fibrin clots against fibrinolysis.
4. Therapeutic Indications & Evidence-Supported Uses
- Heavy menstrual bleeding (menorrhagia)
- postpartum haemorrhage (WOMAN trial protocol)
- acute trauma haemorrhage (CRASH-2/3 protocol within 3 hours)
- surgical/dental bleeding
- hereditary angioedema
- melasma (low-dose off-label)
🇮🇳 Jurisdiction & Indication Note: Indications and schedules reflect Indian compendial and regulatory records (CDSCO / Indian Pharmacopoeia & NFI / NLEM 2022). Where international reference labels (US FDA DailyMed / NCBI StatPearls) are cited for pharmacokinetic or mechanistic parameters, international approvals do not automatically imply CDSCO approval in India.
5. Educational Dosage Context, Formulations & Administration
Educational Dosing & Regimen Summary: Adult: Menorrhagia: 1 g (two 500 mg tablets) PO TDS-QDS for up to 4 days during menses (max 4 g/day). Trauma / Postpartum Haemorrhage: 1 g IV slowly over 10 min within 3 hours of onset, followed if needed by 1 g IV over 8 hours. • Paediatric: Major Bleeding / Trauma: 15-20 mg/kg (max 1 g) slow IV over 10 min.
Administration & Meal Timing: See Administration & Counselling below. | Standard clinical schedule per indication.
6. Pharmacokinetics, Metabolism & Renal/Hepatic Adjustment
Absorption, distribution, metabolism, and excretion follow class pharmacokinetic profile; verify patient renal/hepatic function.
Renal: Excreted >95% unchanged in urine. Serum Creatinine 1.4-2.8 mg/dL: 10 mg/kg IV BD (or 50% oral dose); SCr 2.8-5.7 mg/dL: 10 mg/kg IV OD; SCr >5.7 mg/dL: 10 mg/kg IV q48h. • Hepatic: No dose adjustment required in hepatic impairment.
Renal: Excreted >95% unchanged in urine. Serum Creatinine 1.4-2.8 mg/dL: 10 mg/kg IV BD (or 50% oral dose); SCr 2.8-5.7 mg/dL: 10 mg/kg IV OD; SCr >5.7 mg/dL: 10 mg/kg IV q48h. • Hepatic: No dose adjustment required in hepatic impairment.
Renal: Excreted >95% unchanged in urine. Serum Creatinine 1.4-2.8 mg/dL: 10 mg/kg IV BD (or 50% oral dose); SCr 2.8-5.7 mg/dL: 10 mg/kg IV OD; SCr >5.7 mg/dL: 10 mg/kg IV q48h. • Hepatic: No dose adjustment required in hepatic impairment.
7. Contraindications, Precautions & High-Risk Warnings
- Contraindications: Active thromboembolic disease (DVT, PE, cerebral thrombosis); subarachnoid haemorrhage; macroscopic haematuria from upper urinary tract (causes ureteric clot colic and obstruction); history of convulsions; NEVER administer intrathecally/epidurally. • Precautions: CATASTROPHIC LOOK-ALIKE AMPULE HAZARD: Tranexamic acid ampoules closely resemble Bupivacaine heavy spinal anaesthesia ampoules—accidental intrathecal injection causes refractory status epilepticus, ventricular arrhythmias, and >50% mortality! Store Tranexamic acid ampoules AWAY from spinal anaesthetic drugs.
Key Clinical Precautions: Renal: Excreted >95% unchanged in urine. Serum Creatinine 1.4-2.8 mg/dL: 10 mg/kg IV BD (or 50% oral dose); SCr 2.8-5.7 mg/dL: 10 mg/kg IV OD; SCr >5.7 mg/dL: 10 mg/kg IV q48h. • Hepatic: No dose adjustment required in hepatic impairment.
8. Adverse Effects Profile
- Nausea, vomiting, diarrhoea, dizziness.
- Venous or arterial thrombosis, retinal artery/vein occlusion, colour vision disturbance, convulsions (high IV doses in renal failure).
- Monitor for severe hypersensitivity, organ toxicity, or dose-limiting adverse events.
9. Major Drug–Drug, Drug–Food & Drug–Herb Interactions
- Combined oral contraceptives / Prothrombin complex concentrates / Factor IX -> increased thrombotic risk; Fibrinolytics (Alteplase, Streptokinase) -> mutual antagonism
10. Clinical Monitoring, Patient Counselling & Storage
Clinical & Laboratory Monitoring: Monitor clinical response, baseline renal/hepatic parameters, and relevant serum biomarkers.
Pharmacist Patient Counselling Points:
- Patient Counselling Checklist: For heavy periods, start tablets only after menstrual bleeding begins (for 3-5 days per cycle); stop immediately and seek medical care if leg swelling, chest pain, or visual changes occur.
- Meal & Clock Timing Instruction: See Administration & Counselling below. (Standard clinical schedule per indication.)
- Missed Dose Protocol: Take as soon as remembered unless close to next scheduled dose; never double the dose.
- Geriatric Dispensing Pearl: Schedule: Schedule H | NLEM 2022: Yes | Compendia: IP 2026 / NFI 7th Ed 2026 / NLEM 2022 / CDSCO Schedule H / BNF 90th Ed
Storage, Stability & Dispensing Safeguards: Store below 25°C–30°C in original moisture- and light-resistant packaging out of reach of children. Available forms: Tablet: 250 mg, 500 mg, 650 mg SR; Injection: 500 mg/5 mL (100 mg/mL ampoule).
11. Visual Pharmacology & Mechanism Diagram (svg-v339-01-adme-12-step-journey)
12. Authoritative References, Regulatory Sources & Editorial Disclaimer
Primary Compendial & Guideline Reference: Indian Pharmacist Desk Reference — Professional Edition 2.7 (2026–27) • Ch 12 [12.13] (p. 161)
Official Verification Portals: Indian Pharmacopoeia Commission (IPC) & National Formulary of India (NFI) • Central Drugs Standard Control Organization (CDSCO) • Ministry of Health & Family Welfare — NLEM 2022 • NCBI Bookshelf / StatPearls Pharmacology Reference • DailyMed (US FDA Official Prescribing Reference)
Last Medically & Pharmaceutically Reviewed: 2026-11-10 • Verification Status: HANDBOOK_SOURCE_CONTENT
Educational & Clinical Disclaimer: This reference profile is published solely for pharmacy education, academic study, and professional clinical reference. It does not substitute for patient-specific clinical judgement, qualified specialist oncology/medical supervision, or official CDSCO/IP prescribing information. Never self-medicate with prescription, Schedule H/H1/X, NDPS, or oncology medicines.
13. Related Reference Monographs, Educational Guides & Visual Concept
💊 Related Pharmacological / Category Profiles
- [12.14] Misoprostol (PGE1 Analogue — Obstetric & GI Ulcer Protocol) — Synthetic Prostaglandin E1 Analogue (Oxytocic / Cervical Ripening
- [12.15] Mifepristone (Antiprogestogen — Medical Termination Combi-Pack) — Synthetic Steroidal Antiprogestogen & Antiglucocorticoid (Progest
- [12.16] Magnesium Sulphate Injection (Parenteral IV/IM Pritchard & Zuspan Eclampsia Regimen) — Parenteral Anticonvulsant in Eclampsia, Electrolyte Replenisher &
- [12.17] Oxytocin, Methylergometrine Maleate & Carboprost — High-Alert Obstetric Uterotonics (Neurohypophyseal Peptide, Ergot